Reviva Pharmaceuticals (RVPH) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Document Information [Line Items]
Entity Central Index Key	0001742927
Amendment Flag	false
Current Fiscal Year End Date	--12-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38634
Entity Registrant Name	Reviva Pharmaceuticals Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-4306526
Entity Address, Address Line One	19925 Stevens Creek Blvd., Suite 100
Entity Address, City or Town	Cupertino
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95014
City Area Code	408
Local Phone Number	501-8881
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RVPH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,442,871

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Assets
Cash	$ 23,191,927	$ 29,687,944
Prepaid expenses and other current assets	849,023	1,716,057
Total Assets	24,040,950	31,404,001
Liabilities
Accounts payable	2,347,798	509,583
Accrued expenses and other current liabilities	1,227,934	1,835,228
Total current liabilities	3,575,732	2,344,811
Warrant liabilities	105,699	372,730
Total Liabilities	3,681,431	2,717,541
Commitments and contingencies
Stockholders' equity
Common stock, par value of $0.0001; 115,000,000 shares authorized; 20,442,871 and 14,433,286 shares issued and outstanding as of September 30, 2022, and December 31, 2021, respectively	2,044	1,443
Additional paid-in capital	103,410,464	95,516,986
Accumulated deficit	(83,052,989)	(66,831,969)
Total stockholders' equity	20,359,519	28,686,460
Total Liabilities and Stockholders' Equity	$ 24,040,950	$ 31,404,001

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited)-parentheticals (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	115,000,000	115,000,000
Common Stock, Shares, Issued (in shares)	20,442,871	14,433,286
Common Stock, Shares, Outstanding, Ending Balance (in shares)	20,442,871	14,433,286

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Research and development	$ 2,305,981	$ 1,423,359	$ 12,650,388	$ 2,188,849
General and administrative	1,256,972	1,053,481	3,882,210	3,951,021
Total operating expenses	3,562,953	2,476,840	16,532,598	6,139,870
Loss from operations	(3,562,953)	(2,476,840)	(16,532,598)	(6,139,870)
Other income (expense)
Gain on remeasurement of warrant liabilities	0	200,273	267,031	1,312,899
Interest and other income (expense), net	49,509	(547)	56,961	(3,948)
Total other income (expense), net	49,509	199,726	323,992	1,308,951
Loss before provision for income taxes	(3,513,444)	(2,277,114)	(16,208,606)	(4,830,919)
Provision for income taxes	1,864	2,102	12,414	6,004
Net loss	$ (3,515,308)	$ (2,279,216)	$ (16,221,020)	$ (4,836,923)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.18)	$ (0.12)	$ (0.87)	$ (0.36)
Weighted average shares outstanding
Basic and diluted (in shares)	19,269,989	18,455,586	18,737,330	13,554,548

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020	9,231,737
Balance at Dec. 31, 2020	$ 923	$ 63,774,920	$ (58,310,093)	$ 5,465,750
Common stock issued in connection with warrant exercises (in shares)	23,849
Common stock issued in connection with warrant exercises	$ 2	98,375	0	98,377
Issuance of common stock and warrants in offering, net of transaction costs (in shares)	4,133,400
Issuance of common stock and warrants in offering, net of transaction costs	$ 413	31,497,050	0	31,497,463
Stock-based compensation expense	0	44,679	0	44,679
Net loss	$ 0	0	(4,836,923)	(4,836,923)
Balance (in shares) at Sep. 30, 2021	13,388,986
Balance at Sep. 30, 2021	$ 1,338	95,415,024	(63,147,016)	32,269,346
Balance (in shares) at Dec. 31, 2020	9,231,737
Balance at Dec. 31, 2020	$ 923	63,774,920	(58,310,093)	5,465,750
Balance (in shares) at Dec. 31, 2021	14,433,286
Balance at Dec. 31, 2021	$ 1,443	95,516,986	(66,831,969)	28,686,460
Balance (in shares) at Jun. 30, 2021	13,388,986
Balance at Jun. 30, 2021	$ 1,338	95,387,434	(60,867,800)	34,520,972
Stock-based compensation expense	0	27,590	0	27,590
Net loss	$ 0	0	(2,279,216)	(2,279,216)
Balance (in shares) at Sep. 30, 2021	13,388,986
Balance at Sep. 30, 2021	$ 1,338	95,415,024	(63,147,016)	32,269,346
Balance (in shares) at Dec. 31, 2021	14,433,286
Balance at Dec. 31, 2021	$ 1,443	95,516,986	(66,831,969)	28,686,460
Common stock issued in connection with warrant exercises (in shares)	4,033,300
Common stock issued in connection with warrant exercises	$ 403	0	0	403
Issuance of common stock and warrants in offering, net of transaction costs (in shares)	1,976,285
Issuance of common stock and warrants in offering, net of transaction costs	$ 198	7,773,329	0	7,773,527
Stock-based compensation expense	0	120,149	0	120,149
Net loss	$ 0	0	(16,221,020)	(16,221,020)
Balance (in shares) at Sep. 30, 2022	20,442,871
Balance at Sep. 30, 2022	$ 2,044	103,410,464	(83,052,989)	20,359,519
Balance (in shares) at Jun. 30, 2022	15,133,286
Balance at Jun. 30, 2022	$ 1,513	95,596,548	(79,537,681)	16,060,380
Common stock issued in connection with warrant exercises (in shares)	3,333,300
Common stock issued in connection with warrant exercises	$ 333	0	0	333
Issuance of common stock and warrants in offering, net of transaction costs (in shares)	1,976,285
Issuance of common stock and warrants in offering, net of transaction costs	$ 198	7,773,329	0	7,773,527
Stock-based compensation expense	0	40,587	0	40,587
Net loss	$ 0	0	(3,515,308)	(3,515,308)
Balance (in shares) at Sep. 30, 2022	20,442,871
Balance at Sep. 30, 2022	$ 2,044	$ 103,410,464	$ (83,052,989)	$ 20,359,519

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (3,515,308)	$ (2,279,216)	$ (16,221,020)	$ (4,836,923)
Adjustments to reconcile net loss to net cash used in operating activities
Change in fair value of warrant liabilities			(267,031)	(1,312,899)
Stock-based compensation expense			120,149	44,679
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			1,074,587	(302,123)
Accounts payable			1,630,662	(587,263)
Accrued expenses and other current liabilities			(607,294)	228,220
Net cash used in operating activities			(14,269,947)	(6,766,309)
Cash flows from financing activities
Proceeds from issuance common stock and warrants in offering, net			7,773,527	31,497,463
Proceeds from exercise of warrants			403	0
Net cash provided by financing activities			7,773,930	31,497,463
Net (decrease) increase in cash			(6,496,017)	24,731,154
Cash, beginning of period			29,687,944	8,760,462	$ 8,760,462
Cash, end of period	23,191,927	33,491,616	23,191,927	33,491,616	$ 29,687,944
Supplemental disclosures of cash flow information:
Cash paid for taxes			4,981	2,400
Prepaid expenses included in accounts payable	$ 207,553	$ 0	$ 207,553	$ 0

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Operations	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, Reviva Pharmaceuticals Holdings, Inc. (the “Company”), a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp. (“Tenzing”), a British Virgin Islands exempted company, Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (“Merger Sub”), and Reviva Pharmaceuticals, Inc., a Delaware corporation (together with its consolidated subsidiary), consummated a business combination (the “Business Combination”) through the merger of Merger Sub with and into Reviva Pharmaceuticals, Inc., contemplated by the previously announced Agreement and Plan of Merger, dated as of July 20, 2020 (the “Merger Agreement”), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals, Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), Merger Sub merged with and into Reviva Pharmaceuticals, Inc., with Reviva Pharmaceuticals, Inc. as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals, Inc. becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings, Inc. (together with its consolidated subsidiary). Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 and its Indian subsidiary, Reviva Pharmaceuticals India Pvt. Ltd. was incorporated in 2014. The Company is an emerging research based pharmaceutical company focused on developing a portfolio of internally discovered next generation safe and effective therapeutic drugs by using an integrated chemical genomics technology platform and proprietary chemistries. The Company is currently focused on developing drugs for the central nervous system (CNS), cardiovascular (CV), metabolic and inflammatory diseases.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain footnotes and other financial information normally required by accounting principles generally accepted in the United States of America, or GAAP, have been condensed or omitted in accordance with such rules and regulations. In management’s opinion, these condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and notes thereto and include all adjustments, consisting of normal recurring items, considered necessary for the fair presentation. The operating results for the nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, has been derived from our audited financial statements at that date but does not include all disclosures and financial information required by GAAP for complete financial statements. The information included in the quarterly report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2021, which were included in our annual report on Form 10-K, as filed with the Securities and Exchange Commission on March 15, 2022. Liquidity and Going Concern The Company has recognized recurring losses. As of September 30, 2022 the Company had a working capital of approximately $20.5 million, an accumulated deficit of $83.1 million and cash on hand of approximately $23.2 million. The Company’s net loss for the three months ended September 30, 2022 and 2021, was approximately $3.5 million and $2.3 million, respectively. The Company’s net loss for the nine months ended September 30, 2022 and 2021, was approximately $16.2 million and $4.8 million, respectively. The Company expects to incur significant expenses and increased operating losses for the next several years. The Company expects its expenses to increase in connection with its ongoing activities to research, develop and commercialize its product candidates. The Company will need to generate significant revenues to achieve profitability, and it may never do so. The Company expects the balance of cash on hand to be sufficient to meet its obligations for the 12 months from the issuance of these consolidated financial statements. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances. Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash is held in demand deposit form by one financial institution. The Company has not experienced any losses on its deposits of cash. The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors. Impact of COVID-19 In response to the spread of COVID-19, the Company has taken temporary precautionary measures intended to help minimize the risk of the virus to its employees and community, including temporarily requiring employees to work remotely and suspending all non-essential travel for the Company’s employees. As a result of the COVID-19 pandemic, the Company may experience disruptions that could adversely impact the Company’s business. The COVID-19 pandemic may negatively affect clinical site initiation, patient recruitment and enrollment, patient dosing, distribution of drug to clinical sites and clinical trial monitoring for our clinical trials. The COVID-19 pandemic may also negatively affect the operations of the third-party contract research organizations that the Company intends to rely upon to assist it in conducting its clinical trials and the contract manufacturers who manufacture the Company’s drug candidates. The Company is continuing to assess the potential impact of the COVID-19 pandemic on its business and operations as of September 30, 2022.

Note 3 - Public Offering

Note 3 - Public Offering	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	3. PUBLIC OFFERING On June 1, 2021, the Company completed a public offering (the “Offering”) of Units (each, a “Unit”), with each Unit consisting of (a) one share of common stock (or pre-funded warrant to purchase one

Note 4 - Registered Direct Offe

Note 4 - Registered Direct Offering and Private Placement	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	3. PUBLIC OFFERING On June 1, 2021, the Company completed a public offering (the “Offering”) of Units (each, a “Unit”), with each Unit consisting of (a) one share of common stock (or pre-funded warrant to purchase one
Registered Direct Offering and Private Placement [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	4. REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT On September 8, 2022, the Company completed a registered direct offering and concurrent private placement (together, the “September 2022 Offering”). In the registered direct offering, the Company issued 1,976,285 shares of common stock at a purchase price per share of $2.53, for aggregate gross proceeds to the Company of approximately $5.0 million, before deducting certain transaction expenses payable by the Company. The transaction expenses were net against the proceeds received and were included in additional paid-in capital. The Company issued to the investors in the September 2022 Offering warrants to purchase up to 3,359,684 shares of common stock (the “Private Placement Warrants”). The Private Placement Warrants were immediately exercisable upon issuance at an exercise price of $2.40 per share and will expire on September 8, 2027. In a concurrent private placement the Company issued pre-funded warrants (the “Private Pre-Funded Warrants”) to purchase up to an aggregate of 1,383,399 shares of common stock at a purchase price of $2.5299 per Private Pre-Funded Warrant, for aggregate gross proceeds to the Company of approximately $3.5 million, before deducting transaction expenses payable by the Company, which were net against the proceeds received and were included in additional paid-in capital. The Private Pre-Funded Warrants were immediately exercisable at an exercise price of $0.0001 per share and will expire when the Private Pre-Funded Warrants are fully exercised. No Private Pre-Funded Warrants or Private Placement Warrants have been exercised as of September 30, 2022 (see Note 7). The September 2022 Offering resulted in aggregate gross proceeds of approximately $8.5 million before deducting transaction expenses. The total net proceeds totaled approximately $7.8 million after deducting transaction costs of $0.7 million.

Note 5 - At the Market Offering

Note 5 - At the Market Offering	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
At the Market Offering [Text Block]	5. AT THE MARKET OFFERING In January 2022, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of its common stock for aggregate gross proceeds of up to $12.9 million. Effective July 28, 2022, the Company terminated the ATM Agreement. Prior to termination, the Company had not

Note 6 - Loss Per Share

Note 6 - Loss Per Share	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	6. LOSS PER SHARE Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. Diluted loss per share includes potentially dilutive securities such as stock options, warrants to purchase common stock, and other convertible instruments unless the result of inclusion would be anti-dilutive. These securities have been excluded from the calculation of diluted net loss per shares for the three and nine months ended September 30, 2022 and September 30, 2021 because all such securities are anti-dilutive for all periods presented. The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Shares issuable upon exercise of stock options 179,627 146,698 179,627 146,698 Shares issuable upon exercise of warrants to purchase common stock 17,237,604 13,883,732 17,237,604 13,883,732 Shares contingently issuable for earnout 1,000,000 1,000,000 1,000,000 1,000,000 18,417,231 15,030,430 18,417,231 15,030,430 The diluted loss per share computation equals basic loss per share for the three and nine months ended September 30, 2022 and September 30, 2021 because the Company had a net loss and the impact of the assumed exercise of stock options and warrants would have been anti-dilutive.

Note 7 - Warrants

Note 7 - Warrants	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Warrants [Text Block]	7. WARRANTS As of September 30, 2022, there were public warrants outstanding to purchase an aggregate of 6,325,000 shares of common stock and private warrants outstanding to purchase an aggregate of 3,915,997 shares of common stock. Each public warrant entitles the holder thereof to purchase one We may call the public warrants for redemption, in whole and not in part, at a price of $0.01 per warrant; • if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the third trading business day prior to the notice of redemption to holders of the public warrants, and • if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption • at any time while the public warrants are exercisable • upon not less than 30 days’ prior written notice of redemption to each warrant holder The private warrants are substantially similar to the public warrants except such private warrants; • are exercisable for cash or on a cashless basis, at the holder’s option • cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates. • The redemption price is to be calculated as the 10-day average trading price ending one trading business day prior to the notice of redemption. In no event will the Company be required to net cash settle either the public or the private warrants. The exercise price and number of shares of common stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or a recapitalization, reorganization, merger or consolidation. Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of September 30, 2022, and December 31, 2021. The fair value of these warrants on the date of issuance was $1,279,182. In connection with the September 2022 Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0 million and the Pre-Funded Warrants are exercisable into one In connection with the September 2022 Offering (see note 4), the Company issued Private Placement Warrants to purchase up to 3,359,684 shares of Common Stock, which were immediately exercisable at an exercise price of $2.40 per share and will expire on September 8, 2027. Additionally, the Company issued Private Pre-Funded Warrants to purchase up to an aggregate of 1,383,399 shares of common stock at a purchase price of $2.5299 per share. The Private Pre-Funded Warrants were immediately exercisable at an exercise price of $0.0001 per share. The fair value of the Private Placement Warrants and Private Pre-Funded Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., Company share price of $2.20, exercise price of $2.40 for the Private Placement Warrants and $0.0001 for the Private Pre-Funded Warrants, term of 5 years, volatility of 111%, risk-free rate of 3.4%, and expected dividend rate of 0%) The Company evaluated the Private Placement Warrants and the Private Pre-Funded Warrants in accordance with the guidance at ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging

Note 8 - Stock Option Plans and

Note 8 - Stock Option Plans and Stock-based Compensation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	8. STOCK OPTION PLANS AND STOCK-BASED COMPENSATION Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the three months ended September 30, 2022 and 2021, the Company recorded stock-based compensation of $40,587 and $27,590 respectively. During the nine months ended September 30, 2022, and 2021, the Company recorded stock-based compensation of $120,149 and $44,679 respectively. As of September 30, 2022, the Company had unrecognized stock-based compensation expense of $163,779, which is expected to be recognized over a weighted-average period of 1.5 years. As of September 30, 2022, there are 0 and 2,695,663 shares of common stock available for issuance under the 2006 Equity Incentive Plan and 2020 Equity Incentive Plan. Determining Fair Value Valuation and Recognition – The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term – Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term. Dividend Yield – The Company has not paid a dividend and does not anticipate paying a dividend in the foreseeable future. The value of option grants is calculated using the Black-Scholes option pricing model with the following assumptions for options granted during the nine months ended September 30, 2022 and 2021: September 30, 2022 September 30, 2021 Risk-free interest rate 2.95% 0.95% - 1.10% Expected term (in years) 5.45 5.75 - 6.08 Expected volatility 86.6% 91.4% - 92.2% Expected dividend yield 0% 0% Activity under the stock plans for the nine months ending September 30, 2022, is as follows: Number of Options Outstanding Weighted Average Exercise price per share Weighted Average Remaining Contractual Term in Years Balance, December 31, 2021 192,898 $ 8.46 6.76 Granted 5,000 $ 0.71 Expired (18,271 ) $ 11.89 Balance, September 30, 2022 179,627 $ 7.89 6.74 Balance at September 30, 2022 179,627 $ 7.89 6.74 Options exercisable at September 30, 2022 101,674 $ 10.91 5.12

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. COMMITMENTS AND CONTINGENCIES Clinical trials Since 2010, the Company has entered into multiple clinical trial agreements with medical institutions in the United States, Europe and Asia for the purpose of enrolling patients into various clinical trials. The agreements are substantially similar by trial and include a detailed listing of the clinical trial services for which the Company will pay, how much will be paid for each service, a set-up charge (if any), Investigational Review Board fees, contractual term, and other provisions. The clinical trial services provided by each site generally include the screening of prospective patients and, for those patients to be enrolled in the study, administration of the Company’s investigation drug according to the trial protocol, any required hospitalization, ancillary medical supplies, and 2-week patient follow-up. Further, each agreement requires the Company to indemnify each respective clinical site against any and all liability, loss, or damage it may suffer as a result of third-party claims; the Company maintains product liability insurance of not less than $10 million in conjunction with this indemnification. The agreements may be terminated upon 30 days’ written notice, subject to conditions of paying all liabilities incurred through the date of termination. Additionally, with each screened patient, the Company incurs expense with other entities engaged to provide independent review of patient medical records. Indemnification From time to time, in its normal course of business, the Company may indemnify other parties, with whom it enters into contractual relationships, including lessors and parties to other transactions with the Company. The Company may agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or third-party infringement claims. It may not be possible to determine the maximum potential amount of liability under such indemnification obligations due to the unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. Historically, there have been no such indemnification claims. The Company has also indemnified its directors and executive officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual may be involved by reason of such individual being or having been a director or executive officer. Operating Leases The Company adopted ASC 842, Leases, on January 1, 2020. The Company has elected to apply the short-term lease exception to leases of one year or less. Presently, the Company has a single twelve-month

Note 10 - Fair Value Measuremen

Note 10 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	10. FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: • Level 1 - quoted prices in active markets for identical assets or liabilities; • Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or • Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a listing of the Company’s warrant liabilities required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of September 30, 2022 and December 31, 2021: September 30, 2022 Level 1 Level 2 Level 3 Total (unaudited) Liabilities: Warrant liability — — $ 105,699 $ 105,699 Total $ — $ — $ 105,699 $ 105,699 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ 372,730 $ 372,730 Total $ — $ — $ 372,730 $ 372,730 The following table summarizes the changes in the fair value of the warrant liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Balance, beginning of period $ 105,699 $ 851,159 $ 372,730 $ 1,963,785 Change in fair value of warrant liability — (200,273 ) (267,031 ) (1,312,899 ) Balance, end of period $ 105,699 $ 650,886 $ 105,699 $ 650,886 The Company classifies the private warrants pursuant to ASC 815 as derivative liabilities as the warrants have terms which are modified upon any future transfer of ownership, with subsequent changes in their fair values to be recognized in the consolidated financial statements at each reporting date. The Company calculated the fair value of the private warrants as of September 30, 2022 as $105,699 using a Black-Scholes model. The key inputs used in the Black-Scholes calculation were, the risk-free interest rate, expected volatility, expected life, exercise price and stock price. The risk-free interest rate was estimated to be 4.23%, the expected volatility was estimated to be 76.8 11.50 The Company recorded a gain on remeasurement of warrant liabilities of $0 and $200,273 for the three months ended September 30, 2022 and 2021, respectively. The Company recorded a gain on remeasurement of warrant liabilities of $267,031 and $1,312,899 for the nine months ended September 30, 2022 and 2021, respectively.

Note 11 - Subsequent Events

Note 11 - Subsequent Events	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	11. SUBSEQUENT EVENTS In connection with the September 2022 Offering, on October 6, 2022, the Company filed a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended, relating to the resale from time to time, by the selling stockholders identified in the prospectus of (i) up to 3,359,684 shares of common stock, which the selling stockholders may acquire upon the exercise the Private Placement Warrants and (ii) up to 1,383,399 shares of common stock which the selling stockholders may acquire upon the exercise of the Private Pre-Funded Warrants. The Company issued the Private Placement Warrants and the Private Pre-Funded Warrants to the selling stockholders in the September 2022 Offering on September 8, 2022. On October 17, 2012, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-1. The Company will not receive any proceeds from the sale of the shares by the selling stockholders.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
Going Concern [Policy Text Block]	Liquidity and Going Concern
Use of Estimates, Policy [Policy Text Block]	Use of estimates
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk and other risks and uncertainties
Impact of COVID-19 [Policy Text Block]	Impact of COVID-19

Note 6 - Loss Per Share (Tables

Note 6 - Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Shares issuable upon exercise of stock options 179,627 146,698 179,627 146,698 Shares issuable upon exercise of warrants to purchase common stock 17,237,604 13,883,732 17,237,604 13,883,732 Shares contingently issuable for earnout 1,000,000 1,000,000 1,000,000 1,000,000 18,417,231 15,030,430 18,417,231 15,030,430

Note 8 - Stock Option Plans a_2

Note 8 - Stock Option Plans and Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	September 30, 2022 September 30, 2021 Risk-free interest rate 2.95% 0.95% - 1.10% Expected term (in years) 5.45 5.75 - 6.08 Expected volatility 86.6% 91.4% - 92.2% Expected dividend yield 0% 0%
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Outstanding Weighted Average Exercise price per share Weighted Average Remaining Contractual Term in Years Balance, December 31, 2021 192,898 $ 8.46 6.76 Granted 5,000 $ 0.71 Expired (18,271 ) $ 11.89 Balance, September 30, 2022 179,627 $ 7.89 6.74 Balance at September 30, 2022 179,627 $ 7.89 6.74 Options exercisable at September 30, 2022 101,674 $ 10.91 5.12

Note 10 - Fair Value Measurem_2

Note 10 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	September 30, 2022 Level 1 Level 2 Level 3 Total (unaudited) Liabilities: Warrant liability — — $ 105,699 $ 105,699 Total $ — $ — $ 105,699 $ 105,699 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ 372,730 $ 372,730 Total $ — $ — $ 372,730 $ 372,730
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Balance, beginning of period $ 105,699 $ 851,159 $ 372,730 $ 1,963,785 Change in fair value of warrant liability — (200,273 ) (267,031 ) (1,312,899 ) Balance, end of period $ 105,699 $ 650,886 $ 105,699 $ 650,886

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Working Capital Deficit	$ 20,500,000		$ 20,500,000
Retained Earnings (Accumulated Deficit), Total	83,052,989		83,052,989		$ 66,831,969
Cash	23,200,000		23,200,000
Net Income (Loss) Attributable to Parent, Total	$ 3,515,308	$ 2,279,216	$ 16,221,020	$ 4,836,923

Note 3 - Public Offering (Detai

Note 3 - Public Offering (Details Textual) - USD ($)			3 Months Ended	9 Months Ended
	Sep. 08, 2022	Jun. 01, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Proceeds from Issuance or Sale of Equity, Net	$ 7,800,000			$ 7,773,527	$ 31,497,463
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,976,285	1,976,285	4,133,400
Public Offering [Member]
Number of Units, One, Issued (in shares)		4,133,400
Number of Units, Two, Issued (in shares)		5,066,600
Shares Issued, Price Per Share, One (in dollars per share)		$ 3.75
Shares Issued, Price Per Share, Two (in dollars per share)		$ 3.7499
Proceeds from Issuance or Sale of Equity, Net		$ 31,500,000
Payments of Stock Issuance Costs		$ 3,000,000
Public Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		4,133,400
Over-Allotment Option [Member]
Number of Units, One, Issued (in shares)		1,200,000
Pre-Funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	5,066,600	5,066,600
Investor Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.125	$ 4.125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,900,000	6,900,000

Note 4 - Registered Direct Of_2

Note 4 - Registered Direct Offering and Private Placement (Details Textual) - USD ($)		9 Months Ended
	Sep. 08, 2022	Sep. 30, 2022	Sep. 30, 2021
Proceeds from Issuance or Sale of Equity, Total	$ 8,500,000
Proceeds from Issuance or Sale of Equity, Net	7,800,000	$ 7,773,527	$ 31,497,463
Issuance of Equity, Transaction Costs	$ 700,000
Private Placement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.40
Private Placement Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,359,684
Private Pre-funded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Class of Warrant or Right, Purchase Price Per Warrant or Right	$ 2.5299
Proceeds from Issuance of Warrants	$ 3,500,000
Private Pre-funded Warrant [Member] | Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,383,399
Registered Direct Offering and Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,976,285
Shares Issued, Price Per Share	$ 2.53
Proceeds from Issuance of Common Stock	$ 5,000,000

Note 5 - At the Market Offeri_2

Note 5 - At the Market Offering (Details Textual) - H.C. Wainwright & Co [Member] - The Market Offering Agreement "ATM Agreement" [Member] - USD ($) shares in Thousands, $ in Millions	1 Months Ended
	Jan. 31, 2022	Jul. 28, 2022
Sale of Stock Agreement, Maximum Aggregate Gross Proceeds	$ 12.9
Shares, Issued (in shares)		0

Note 6 - Loss Per Share - Antid

Note 6 - Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive securities (in shares)	18,417,231	15,030,430	18,417,231	15,030,430
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	179,627	146,698	179,627	146,698
Warrant [Member]
Antidilutive securities (in shares)	17,237,604	13,883,732	17,237,604	13,883,732
Earn-out Shares [Member]
Antidilutive securities (in shares)	1,000,000	1,000,000	1,000,000	1,000,000

Note 7 - Warrants (Details Text

Note 7 - Warrants (Details Textual)			9 Months Ended		12 Months Ended
	Sep. 08, 2022 USD ($) $ / shares shares	Jun. 01, 2021 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares
Proceeds from Warrant Exercises | $			$ 403	$ 0
Share Price | $ / shares	$ 2.20		$ 1.59
Public Warrants [Member]
Class of Warrant or Right, Outstanding			6,325,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 11.50
Class of Warrant or Right, Redemption Price Per Share | $ / shares			0.01
Threshold Closing Price for Specified Number of Trading Days | $ / shares			$ 21
Threshold Trading Days for Sale of Shares (Day)			20 days
Threshold Consecutive Trading Days for Sale of Shares (Day)			30 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			126,268
Warrants and Rights Outstanding | $					$ 1,279,182
Private Warrants [Member]
Class of Warrant or Right, Outstanding			3,915,997
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 11.50
Private Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			0.903
Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0.0423
Pre-Funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	5,066,600	5,066,600
Proceeds from Issuance of Warrants | $		$ 19,000,000
Class of Warrant or Right, Exercised During Period (in shares)			4,033,300		1,033,300
Proceeds from Warrant Exercises | $			$ 403		$ 103
Stock Issued During Period, Shares, Warrants Exercised (in shares)			4,033,300		1,033,300
Investor Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 4.125	$ 4.125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,900,000	6,900,000
Private Placement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.40
Private Placement Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,359,684
Private Pre-funded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.0001
Proceeds from Issuance of Warrants | $	$ 3,500,000
Class of Warrant or Right, Purchase Price Per Warrant or Right | $ / shares	$ 2.5299
Private Pre-funded Warrant [Member] | Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,383,399
Private Placement Warrants and Private Pre-funded Warrants [Member]
Warrants and Rights Outstanding | $	$ 5,712,592
Warrants and Rights Outstanding, Term	5 years
Private Placement Warrants and Private Pre-funded Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.11
Private Placement Warrants and Private Pre-funded Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.034
Private Placement Warrants and Private Pre-funded Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0

Note 8 - Stock Option Plans a_3

Note 8 - Stock Option Plans and Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expense	$ 40,587	$ 27,590	$ 120,149	$ 44,679
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 163,779		$ 163,779
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			1 year 6 months
Equity Incentive Plan 2006 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	0		0
Equity Incentive Plan 2020 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	2,695,663		2,695,663

Note 8 - Stock Option Plans a_4

Note 8 - Stock Option Plans and Stock-based Compensation - Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Risk-free interest rate	2.95%
Risk-free interest rate, minimum		0.95%
Risk-free interest rate, maximum		1.10%
Expected term (in years) (Year)	5 years 5 months 12 days
Expected volatility	86.60%
Expected volatility, minimum		91.40%
Expected volatility, maximum		92.20%
Expected dividend yield	0%	0%
Minimum [Member]
Expected term (in years) (Year)		5 years 9 months
Maximum [Member]
Expected term (in years) (Year)		6 years 29 days

Note 8 - Stock Option Plans a_5

Note 8 - Stock Option Plans and Stock-based Compensation - Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Balance, number of options (in shares)		192,898
Balance, weighted average exercise price (in dollars per share)		$ 8.46
Balance, weighted average remaining term (Year)	6 years 8 months 26 days	6 years 9 months 3 days
Granted, number of options (in shares)	5,000
Granted, weighted average exercise price (in dollars per share)	$ 0.71
Expired, number of options (in shares)	(18,271)
Expired, weighted average exercise price (in dollars per share)	$ 11.89
Balance, number of options (in shares)	179,627
Balance, weighted average exercise price (in dollars per share)	$ 7.89
Options exercisable, number of options (in shares)	101,674
Options exercisable, weighted average exercise price (in dollars per share)	$ 10.91
Options exercisable, weighted average remaining term (Year)	5 years 1 month 13 days

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual)	9 Months Ended
	Sep. 30, 2022 USD ($)
Corporate Office Lease [Member]
Lessee, Operating Lease, Term of Contract (Month)	12 months
Lessee, Operating Lease, Monthly Lease Payment	$ 1,300
Minimum [Member]
General Product Liability Insurance	$ 10,000,000

Note 10 - Fair Value Measurem_3

Note 10 - Fair Value Measurements (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 08, 2022 $ / shares
Share Price | $ / shares	$ 1.59		$ 1.59		$ 2.20
Fair Value Adjustment of Warrants			$ (267,031)	$ (1,312,899)
Private Warrants [Member]
Warrants and Rights Outstanding, Fair Value	$ 105,699		$ 105,699
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 11.50		$ 11.50
Fair Value Adjustment of Warrants	$ 0	$ 200,273	$ 267,031	$ 1,312,899
Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0423		0.0423
Private Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.903		0.903
Private Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	3.21		3.21

Note 10 - Fair Value Measurem_4

Note 10 - Fair Value Measurements - Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Warrant liability	$ 105,699	$ 372,730
Total	105,699	372,730
Fair Value, Inputs, Level 3 [Member]
Warrant liability	105,699	372,730
Total	$ 105,699	$ 372,730

Note 10 - Fair Value Measurem_5

Note 10 - Fair Value Measurements - Fair Value Liability Reconciliation Level 3 (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Balance, beginning of period	$ 105,699	$ 851,159	$ 372,730	$ 1,963,785
Change in fair value of warrant liability	0	(200,273)	(267,031)	(1,312,899)
Balance, end of period	$ 105,699	$ 650,886	$ 105,699	$ 650,886

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - Maximum [Member]	Sep. 08, 2022 shares
Private Placement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,359,684
Private Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,383,399